RADNOR, PA / ACCESSWIRE / June 3, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States ...

June 3, 2024) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ: ...

Akero Therapeutics press release (NASDAQ:AKRO): Q1 GAAP EPS of -$0.90 beats by $0.05. Akero's cash, cash equivalents and short-term marketable securities as of March 31, 2024, were $903.7 million.

Akero Therapeutics, Inc. (AKRO) Securities Fraud Class Action: Akero Therapeutics, a biopharmaceutical company developing treatments for liver disease, is facing a securities class action lawsuit ...

LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage ...

May 10, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by ...

BofA Securities raised the price target for the Akero Therapeutics Inc (NASDAQ:AKRO) stock to “a Neutral”. The rating was released on April 22, 2024, according to finviz. The research report from UBS ...

Akero Therapeutics (NASDAQ:AKRO) just reported results for the first quarter of 2024. Akero Therapeutics reported earnings per share of -90 cents. This was above the analyst estimate for EPS of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...